Update on the treatment of chronic kidney disease-mineral and bone disorder

Journal of Renal Care

Volumn 35, Issue SUPPL. 1, 2009, Pages 19-27

  Bover, Jordi ^a,b   Farré, Neus ^a,b   Andrés, Enric ^a,b   Canal, Cristina ^a,b   Olaya, María Teresa ^a,b   Alonso, Maite ^a,b   Quílez, Begoña ^a,b   Ballarín, José ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b REDINREN   (Spain)

Author keywords

Calcimimetics; Chronic kidney disease; CKD; CKD MBD; Lanthanum; Paricalcitol; Phosphorus binders; Secondary hyperparathyroidism; Sevelamer; Vascular calcification; Vitamin D

Indexed keywords

ALUMINUM DERIVATIVE; CALCIUM CARBONATE; CHELATING AGENT; CINACALCET; DRUG DERIVATIVE; LANTHANUM; LANTHANUM CARBONATE; NAPHTHALENE DERIVATIVE; PHOSPHORUS; POLYAMINE; SEVELAMER; VITAMIN D;

BLOOD; CALCINOSIS; CHRONIC KIDNEY FAILURE; DIETETICS; EDUCATION; HUMAN; METHODOLOGY; NEPHROLOGY; NUTRITIONAL ASSESSMENT; NUTRITIONAL VALUE; ORGANIZATION AND MANAGEMENT; PARATHYROIDECTOMY; PATIENT CARE; PATIENT EDUCATION; PRACTICE GUIDELINE; PROTEIN RESTRICTION; RENAL OSTEODYSTROPHY; REVIEW; STANDARD;

ALUMINUM COMPOUNDS; CALCINOSIS; CALCIUM CARBONATE; CHELATING AGENTS; DIET, PROTEIN-RESTRICTED; DIETETICS; HUMANS; KIDNEY FAILURE, CHRONIC; LANTHANUM; NAPHTHALENES; NEPHROLOGY; NUTRITION ASSESSMENT; NUTRITIVE VALUE; PARATHYROIDECTOMY; PATIENT CARE TEAM; PATIENT EDUCATION AS TOPIC; PHOSPHORUS; POLYAMINES; PRACTICE GUIDELINES AS TOPIC; RENAL OSTEODYSTROPHY; VITAMIN D;

EID: 61649098636     PISSN: 17556678     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2009.00049.x     Document Type: Review

References (66)

1. Almadén Y., Canalejo A., Hernández A. et al. (1996). Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 11 (7), 970-976.
2. Andress D.L. (2006). Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 69, 33-43.
3. Arenas M.D., Malek T, Gil M.T. et al. (2008). Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era. Nefrologia 28(2), 168-173.
4. Bas A., Lopez I., Perez J. et al. (2006). Reversibility of calcitriol-incluced medial artery calcification in rats with intact renal function. J Bone Miner Res 21(3), 484-490.
5. Block G.A., Klassen P.S., Lazarus J.M. et al. (2004). Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15, 2208-2218.
6. Block G.A., Raggi P., Bellasi A. et al. (2007). Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71, 438-441.
7. Block G.A., Spiegel D.M., Ehrlich J. et al. (2005). Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 65(4), 1815-1824.
8. Block G.A., Martin K.J., de Francisco A.L. et al. (2004). Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. New Eng J Med 350(15), 1516-1525.
9. Bover J, Canal C., Marco H. et al. (2008). Diagnostic procedures and rationale for specific therepies in chronic kideny disease-mineral and bone disorder. Contrib Nephrol. 161, 222-33.
10. Bover J., Canal C., Pérez S.G. et al. (2007). Slowing the progression of vascular calcification in chronic kidney disease patients., Eur Ren Dis 1, 1.
11. Bover J., Ortiz-Herbener F., Ballarín J. et al. (2005). New therapy strategies in secondary hyperparathyroidism on dialysis (1): new concepts, new treatments. Nefrologia 25(Suppl 2), 100-108.
12. Bover J., Jara A., Trinidad P. et al. (1994a). The calcemic response to PTH in the rat: effect of elevated PTH levels and uremia. Kidney Int 46(3), 855-861.
13. Bover J., Rodríguez M., Trinidad P. et al. (1994b). Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat. Kidney Int 45(4), 953-961.
14. Cardús A., Panizo S., Parisi E. et al. (2007). Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 22, 860-866.
15. Casey J., Li C.H., Johnsson V. et al. (2006). Multidisciplinary approach for prescriptive management of mineral and bone metabolism in chronic kidney disease: development of a dietetic led protocol. J Ren Care 32(4), 187-191.
16. Chertow G.M., Burke S.K. & Raggi P. (2002). Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62(1), 245-252.
17. Coyne D., Acharya M., Qiu P. et al. (2006). Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47(2), 263-276.
18. Cozzolino M. & Brancaccio D. (2007). Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate. Int J Artif Organs 30(4), 293-300.
19. Craver L., Marco M.P., Martínez I. et al. (2007). Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol Dial Transplant 22(4), 1171-1176.
20. Cunningham J., Danese M., Olson K. et al. (2005). Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68(4), 1793-1800.
21. Fernández-Llama P. & Bover J. (2008). Is albuminuria a marker of arterial remodeling? J Hypertens 26(4), 633-635.
22. Finn W.F., for the SPD 405-307 Lanthanum Study Group. (2006). Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 65(3), 191-202.
23. Go A.S., Chertow G.M., Fan D. et al. (2004). Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. New Eng J Med 351(13), 1296-1305.
24. Goodman W.G., Goldin J., Kuizon B.D. et al. (2000). Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 42(20), 1478-1483.
25. Jara A., Felsenfeld A.J., Bover J. et al. (2000). Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease. Kidney Int 58(3), 1023-1032.
26. Kalantar-Zadeh K., Kuwae N., Regidor D.L. et al. (2006). Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70(4), 771-780.
27. Kestenbaum B., Sampson J.N., Rudser K.D. et al. (2005). J Am Soc Nephrol 16(2), 293-295,
28. Kovesdy C.P., Ahmadzadeh S., Anderson J.E. et al. (2008). Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 168(4), 397-403.
29. Kurz P., Monier-Faugere M.C., Bognar B. et al. (1994). Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46(3), 855-861.
30. Levin A., Bakris G.L., Molitch M. et al. (2007). Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71(1), 31-38.
31. Lindner A., Charra B., Sherrard D.J. et al.. (1974) Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290(13), 697-701.
32. Llach F. & Bover J. (2000). Renal osteodystrophies. In The Kidney (ed Brenner B.M.), pp, 2103-2186. Philadelphia: Saunders.
33. London G.M., Marty C., Marchais S.J. et al. (2004). Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15(7), 1943-1951.
34. Lopez I., Mendoza F.J., Aguilera-Tejero E. et al. (2008). The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 73(3), 300-307.
35. Marco M.P., Craver L., Betriu A. et al. (2001). Influence of vitamin D receptor gene polymorphisms on mortality risk in hemodialysis patients. Am J Kidney Dis 38, 965-974.
36. Mehrotra R., Martin K.J., Fishbane S. et al., for the Fosrenol Overview Research Evaluation Study for Early Experience (FORESEE) Study Group. (2008). Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol 3(5), 1437-1445.
37. Mendoza F.J., Lopez I., Montes de Oca A. et al. (2008). Metabolic acidosis inhibits soft tissue calcification in uremic rats. Kidney Int 73, 407-414.
38. Mizobuchi M., Finch J.L., Martin D.R. et al. (2007). Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 72(6), 709-715.
39. Moe S.M. & Chen N.X. (2008). Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 19(2), 213-216.
40. Moe S., Drüeke T, Cunningham J. et al. (2006). Kidney Disease: Improving Global Outcomes (KDIGO): definition, evaluation, and classification of renal osteodystrophy: a position statement from KDIGO. Kidney Int 69, 1945-1953.
41. Moe S.M. & Chertow G.M. (2006). The case against calcium-based phosphate binders. Clin J Am Soc Nephrol 1(4), 697-703.
42. Moe S.M., Chertow G.M., Coburn J.W. et al. (2005). Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCI. Kidney Int 67(2), 760-771.
43. National Kidney Foundation. (2003). K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl 3), S1-S201.
44. Neves K.R., Graciolli F.G., dos Reis L.M. et al. (2007). Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 71(12), 1262-1270.
45. Nikolov I.G., Joki N., Maizel J. et al. (2006). Pleiotropic effects of the non-calcium phosphate binder sevelamer. Kidney Int Suppl 70(105), S16-S23.
46. Persy V.P., Behets G.J., Bervoets A.R. et al. (2006). Lanthanum: a safe phosphate binder. Semin Dial 19(3), 195-199.
47. Qunibi W., Moustafa M., Muenz L.R. et al., for the CARE-2 investigators. (2008). A 1 -year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51(6), 952-965.
48. Russo D., Miranda I., Ruocco C. et al. (2007). The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72(10), 1255-1261.
49. St Peter W.L., Liu J., Weinhandl E. et al. (2008). A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 51(3), 445-454.
50. Schaefer R.M., Bover J., Dellanna F. et al. (2008). Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR study. Clin Nephrol 70(2), 126-134.
51. Sheikh M.S., Maquire J.A., Emmett M. et al. (1989). Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 83(1), 66-73.
52. Shoji T, Shinohara K., Kimoto E. et al. (2004). Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19(1), 179-184.
53. Slatopolsky E., Cozzolino M. & Finch J.L. (2002). Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int 62(4), 1277-1284.
54. Souberbielle J.C., Boutten A., Carlier M.C. et al. (2006). Inter-method variability in PTH measurement: implication for the care CKD patients. Kidney Int 70(2), 345-350.
55. Suki W.N., Zabaneh R., Cangiano J.L. et al. (2007). Effects of sevelamer and calcium-based phosphate binders on mortalityin hemodialysis patients. Kidney Int 72(9), 1130-1137.
56. Teng M., Wolf M., Ofsthun M.N. et al. (2005). Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16(4), 1115-1125.
57. Teng M., Wolf M., Lowrie E. et al. (2003). Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349, 446-456.
58. Tonelli M., Wiebe N., Culleton 8. et al., for the Alberta Kidney Disease Network. (2007). Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 22(10), 2856-2866.
59. Tonelli M., Sacks E, Pfeffer M. et al., for the Cholesterol And Recurrent Events Trial Investigators. (2005). Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112(17), 2627-2633.
60. Torregrosa V., Cannata J., Bover J. et al. (2008). SEN Guidelines. Recommendations of the Spanish Society of Nephrology for managing bone-mineral metabolic alterations in chronic renal disease patients. Nefrologia 28(Suppl 1), 1-22.
61. Uribarri J. (2002). Unrecognized sources of dietary phosphate. Semin Dial 15(5), 376.
62. Uribarri 3. (2007). Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin Dial 20(4), 295-301.
63. Wang T.J., Pencina M.J., Booth S.L. et al. (2008). Vitamin D deficiency and risk of cardiovascular disease. Circulation 117(4), 503-511.
64. Wolf M., Shah A., Gutierrez O. et al. (2007). Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72(8), 1004-1013.
65. Zittermann A. & Koerfer R. (2008). Protective and toxic effects of vitamin D on vascular calcification: Clinical implications. Mol Aspects Med (in press).
66. Zoccali C. (2006). Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 70(1),26-33.